In vitro targeted killing of human endothelial cells by co-incubation of human serum and NGR peptide conjugated human albumin protein bearing α (1-3) galactose epitopes

Oncology Reports

Volumn 11, Issue 3, 2004, Pages 613-616

  Holle, Lori ^b   Song, Wendy ^a   Hicks, Labri ^b   Holle, Eric ^b   Holmes, Lillian ^b   Wei, Yanzhang ^a,b   Li, Jinhua ^b   Wagner, Thomas ^a,b   Yu, Xianzhong ^a,b  

^a CLEMSON UNIVERSITY   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

CD13; Galactose (1,3) galactose terminal carbohydrate epitope; Human umbilical vascular endothelial cells; NGR peptide

Indexed keywords

ANGIOGENESIS INHIBITOR; EPITOPE; GALACTOSE; ISOPROTEIN; MICROSOMAL AMINOPEPTIDASE; PEPTIDE; SERUM ALBUMIN;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; HUMAN; METABOLISM; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD13; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPITOPES; GALACTOSE; HUMANS; MICROSCOPY, FLUORESCENCE; PEPTIDES; PROTEIN ISOFORMS; SERUM ALBUMIN; UMBILICAL VEINS;

EID: 4644356626     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.3.613     Document Type: Article

References (18)

1. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996. (Pubitemid 26272076)
2. Dameron KM, Volpert OV, Tainsky MA and Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombo-spondin-1. Science 265: 1582-1584, 1994. (Pubitemid 24308973)
3. Bikfalvi A and Bicknell R: Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 23: 576-582, 2002. (Pubitemid 35375803)
4. Huang X, Molema G, King S, Watkins L, Edgington TS and Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275: 547-550, 1997. (Pubitemid 27051913)
5. Ran S, Gao B, Duffy S, Watkins L, Rote N and Thorpe PE: Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58: 4646-4653, 1998. (Pubitemid 28480630)
6. Nilsson F, Kosmehl H, Zardi L and Neri D: Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61: 711-716, 2001. (Pubitemid 32128637)
7. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ and Hill SA: ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253, 2002. (Pubitemid 36025246)
8. Arap W, Pasqualini R and Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380, 1998. (Pubitemid 28063372)
9. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE and Pasqualini R: Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038, 1999. (Pubitemid 29439574)
10. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A and Corti A: Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18: 1185-1190, 2000.
11. Cumis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R and Corti A: Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62: 867-874, 2002. (Pubitemid 34126966)
12. Sandrin MS, Vaughan H, Dabkowski PL and McKenzie IF: Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci USA 90: 11391-11395, 1993. (Pubitemid 23354435)
13. Link CJ Jr, Seregina T, Atchison R, Hall A, Muldoon R and Levy JP: Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res 18: 2301-2308, 1998. (Pubitemid 28386511)
14. Galili U: Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol 15: 155-171, 1993.
15. Unfer RC, Hellrung D and Link CJ Jr: Immunity to the alpha(1,3) galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res 63: 987-993, 2003. (Pubitemid 36278429)
16. LaTemple DC, Abrams GT, Zhang SY and Galili U: Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res 59: 3417-3423, 1999. (Pubitemid 29334502)
17. Zhou WZ, Kaneda Y, Huang S, Morishita R and Hoon D: Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine. Gene Ther 6: 1768-1773, 1999. (Pubitemid 29485953)
18. Vaughan HA, Loveland BE and Sandrin MS: Gal alpha(1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. Transplantation 58: 879-882, 1994.